SAVA241129P5500
- 0.00
- 0.000.00%
Cassava Sciences Newsroom
A Post-Mortem on Cassava Sciences
Unpacking the Latest Options Trading Trends in Cassava Sciences
SAVA Stock Plunges 84% on Alzheimer's Drug Failure in Late-Stage Study
What's Left in Cassava After Phase 3 Setback for Alzheimer's Drug
Express News | Cassava Sciences Shares Fall 4% After 84% Slump in Previous Session
Down -83.93% in 4 Weeks, Here's Why You Should You Buy the Dip in Cassava Sciences (SAVA)
This Goldman Sachs Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Cassava Sciences Cut to Neutral From Buy by HC Wainwright & Co.
Cassava Sciences Price Target Announced at $116.00/Share by HC Wainwright & Co.
Cassava Sciences Analyst Ratings
Social Buzz: Wallstreetbets Stocks Mixed Pre-Bell Tuesday; Cassava Sciences to Advance, MicroStrategy to Decline
H.C. Wainwright Downgrades Cassava Sciences(SAVA.US) to Hold Rating
Express News | Cassava Sciences, Inc. : H.c. Wainwright Cuts to Neutral From Buy
Cassava Sciences, Zoom, Kohl's, Rivian, Tesla: Why These 5 Stocks Are On Investors' Radars Today
Cassava Sciences Options Spot-On: On November 25th, 168.87K Contracts Were Traded, With 300.78K Open Interest
12 Health Care Stocks Moving In Monday's Pre-Market Session
Sector Update: Health Care Stocks Advance Late Afternoon
Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October
Express News | Corrected-Buzz-U.S. Stocks on the Move-AMC, Alnylam, Super Micro
'Pharma Bro' Martin Shkreli Tells Investors To 'Short SAVA,' Stock Falls Over 80% After Phase 3 Update